GENZYME CORPORATION for GENZYME CORPORATION
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 2482, Drug Safety Enhancement Act
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Taxation/Internal Revenue Code TAX
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisory |
| MARY MCGRANE | Senior Vice President |
Copyright/Patent/Trademark CPT
H.R. 1249/S. 23, America Invents Act
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Health Issues HCR
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Medicare/Medicaid MMM
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Deficit Reduction Proposals to Joint Committee Changes re: Medicare Part B and Average Sales Price H.R. 2672/S.1423, Preserving Access to Orphan Drugs Act Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.